Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Dr. Qingsong Zhu United States

Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trial outcomes.
Website:
insilico.com
Company Size (Fulltime employees)
51-200
Year of foundation
2014
Partnering Objectives
Please specify your partnering goal
Collaborations on NMEs, therapeutic targets, AI-based generative chemistry
Headquartner in China
Yes
Biotech/Pharma Category
Insilico Medicine US Inc
COO 
Functionality
Business Development

Dr. John Zhu China

Duality Biologics is a China biotech company focusing on the discovery, development and commercialization of new modality biologics to provide solutions to unmet medical needs for grievous diseases in Great China area. Backed by proprietary new modality platform ensuring fast biological validation and development, Duality Biologics has been building a combined pipeline of First-in-class and Best-in-class. Currently, Duality seeks for licensing-in opportunities in broad disease areas especially oncology and autoimmune diseases
Website:
N/A
Company Size (Fulltime employees)
11-50
Partnering Objectives
Please specify your partnering goal
Clinical stage assets in oncology and immunology
Headquartner in China
Yes
Biotech/Pharma Category
Duality Biologics
Founder and CEO 
Functionality
Management

Maya Zhu China

Junshi
Website:
www.junshipharma.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Junshi Bioscience Ltd
Sr Manger BD&L 

Dr. Wei Zhu United States

Allegro 3D is an emerging 3D printing and bioprinting company located in San Diego, a world hub for biotechnology. At the convergence of advanced additive manufacturing, stem cell biology and biomaterials, Allegro 3D’s expertise in bioprinting and biomaterials enables high-throughput manufacturing of advanced biomedical devices, cell matrices and precision human tissues for cell culture, drug screening, therapeutics and regenerative medicine.

Using the world’s most advanced bioprinting technologies developed at the University of California San Diego, Allegro 3D is poised to provide customers with transformational biofabrication solutions that will revolutionize healthcare innovations related to regenerative medicine, drug discovery, and biomedical research.
Website:
https://allegro3d.com
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
Looking for partners in drug discovery, regenerative medicine, and other 3D bioprinting applications.
Headquartner in China
No
Your Research Tool and Service name
Bioprinters, biomaterials, 3D tissues
Service Description
3D bioprinting Tissue engineering Drug screening Regenerative medicine
Target client type
Pharmaceutical, biotech, research institutes, hospitals
Allegro 3D, Inc.
CEO 
Functionality
Management

Don Zinn United States

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your Licensing-in strategy and how we might work together.

Website:
www.crossject.com
Year of foundation
2001
Partnering Objectives
Headquartner in China
No
Assets Information 1
Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis. We also have a Medtech model where we can inject 0.2-0.7ml of your drug (small or large molecule) IM or SQ.
Biotech/Pharma Asset Stage
Medtech Category
Medtech Information 1
needle free auto-injector
Medtech Development Stage
Crossject USA Inc
VP US Business 
Functionality
Business Development

chuhan zong China

A mainland based family fund， heavily investing healthcare and biotechs
Website:
wu-capital.com
Partnering Objectives
Headquartner in China
Yes
Wu Capital
associate 

Fangyue Zou China

Founded in Wuxi, 2017
Focus on development, manufacturing and marketing of drugs
Registered capital is RMB 280M
Consists of Wuxi Fortune, Qingzhipin Pharma and Sihuan Pharma
Annual revenues - RMB 1 billion (~0.5 billion for antibiotics)
To be public company within 5 years in China
Website:
http://www.zh-brimed.com/
Partnering Objectives
Headquartner in China
Yes
BRIMED PHARMA GROUP
Planning Specialist 

Lily Zou

Fosun Pharma USA
CEO 

Vivien Zou United States

Medical Device Company
Website:
https://www.medtronic.com/us-en/index.html
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Learn more about medical device market and industry in China
Headquartner in China
No
Medtech Category
Medtronic
BD head China